A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (HLX10) in Combination With Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (HLX04) in Patients With Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Dose Limiting Toxicity (DLT) of HLX04 plus HLX10 in patients with advanced solid tumors
研究概览
简要总结
This is a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX10-HLX04 combination therapy in patients with advanced solid tumors after failure of standard of care.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years, male or female
- •Patient with histologically or cytologically confirmed advanced malignant solid tumors who have failed standard of care, or has no standard-of-care therapy or are not suitable for standard of care at the present stage;
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1；
- •Life expectancy greater than 3 months;
- •Patient must have at least one measurable tumor lesion as defined by RECIST v1.1; the lesion concerned must not be a bone metastasis if only one target lesion is present;
- •Has adequate organ functions;
- •If the subject is a patient with hepatocellular carcinoma, Child-Pugh classification must be A.
- •A qualified patient (male or female) of childbearing potential must agree to use reliable contraceptive methods (hormonal, or barrier method or abstinence) for the course of the study and through at least 6 months after the last dose; a female patient of childbearing potential must have negative blood pregnancy test within 7 days prior to enrollment;
- •The subject must give his/her informed consent to this study prior to the trial, and voluntarily sign a written informed consent form.
排除标准
- •Histopathological confirmed head and neck cancer or squamous-cell lung cancer, or bleeding tendency in the tumor lesion judged by the investigator;
- •Has received antitumor therapy like radiotherapy, chemotherapy, targeted therapy, endocrinal therapy or immunotherapy, or other clinical study drug therapy within 4 months prior to the initial drug administration;
- •Has received a surgical operation on major viscera or experienced apparent trauma within 4 weeks from the initial drug administration, or experienced subcutaneous venous access device implantation within 7 days;
- •The adverse reactions which occurred in the previous antitumor treatment were not recovered to ≤ grade 1 based on CTCAE 4.03 assessment (except for hair loss);
- •Evidences of metastatic lesion in the patient's central nervous system;
- •Previously experienced ≥ grade 3 immune-related adverse event during immunotherapy;
- •Active, or history of autoimmune disease which may relapse (for example, systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.);
- •Currently having or have had interstitial lung disease;
- •Uncontrollable active infection(s);
- •History of immunodeficiency, including HIV antibody positive;
- •Known active hepatitis B; or hepatitis C virus infections;
- •Has bleeding tendency;
- •History of severe cardiovascular diseases;
- •Known gastrointestinal diseases as follows:
- •Gastrointestinal perforation, abdominal fistula or abdominal abscess within 6 months before signing the informed consent; History of poorly controlled or recurrent inflammatory bowel disease; Active peptic ulcers, or > moderate esophageal varices;
- •Known hypersensitivity to Bevacizumab, or other anti-PD-1, anti-PD-L1 monoclonal antibody agents;
- •Pregnant or breastfeeding female.
研究组 & 干预措施
HLX04+HLX10
HLX10, at three dose levels (1, 3, 10 mg/kg), to be intravenously injected once every two weeks; HLX04, at a fixed dose of 5 mg/kg, intravenously injected once every two weeks; Study drugs given in combination for up to 2 years or until the disease gets worse, whichever comes first.
干预措施: HLX04 (Drug)
HLX04+HLX10
HLX10, at three dose levels (1, 3, 10 mg/kg), to be intravenously injected once every two weeks; HLX04, at a fixed dose of 5 mg/kg, intravenously injected once every two weeks; Study drugs given in combination for up to 2 years or until the disease gets worse, whichever comes first.
干预措施: HLX10 (Drug)
结局指标
主要结局
Dose Limiting Toxicity (DLT) of HLX04 plus HLX10 in patients with advanced solid tumors
时间窗: 28 days
DLT is defined as the occurrence of the following adverse events (unless judged by the investigator to be definitely unrelated to HLX04 or HLX10) within Cycle 1 (i.e., from Cycle 1 Day 1 to Cycle 1 Day 28)
Maximum Tolerated Dose (MTD) of HLX04 plus HLX10 in patients with advanced solid tumors
时间窗: 28 days
The MTD is the dose with toxicity rate (estimated by isotonic regression) most approximate to the target one (30%).
次要结局
- Overall Survival (OS) of HLX04 plus HLX10 in patients with advanced solid tumors(Day 1 of treatment up to 2 years)
- Immunogenicity(Day 1 of treatment up to 2 years)
- Disease Control Rate (DCR) of HLX04 plus HLX10 in patients with advanced solid tumors(Day 1 of treatment up to 2 years)
- Objective Response Rate (ORR) of HLX04 plus HLX10 in patients with advanced solid tumors(Day 1 of treatment up to 2 years)
- PK parameters of the HLX04 plus HLX10 therapy in patients with advanced solid tumors(Day 1 of treatment up to 2 years)
- Progression-Free Survival (PFS) of HLX04 plus HLX10 in patients with advanced solid tumors(Day 1 of treatment up to 2 years)
- Duration of Response (DOR) of HLX04 plus HLX10 in patients with advanced solid tumors(Day 1 of treatment up to 2 years)